Asia Pacific Biopharmaceutical Contract Manufacturing Market
No. of Pages: 145 | Report Code: TIPRE00010854 | Category: Life Sciences
No. of Pages: 145 | Report Code: TIPRE00010854 | Category: Life Sciences
Asian countries are emerging as attractive outsourcing locations for biopharmaceutical industries. Low manufacturing and operating costs in China and India are the key factors that will drive the growth of the biopharmaceutical contract manufacturing market in the region. Recent growth in the biopharmaceutical industry in these countries indicates a positive outlook for this market. Moreover, the growing domestic market and its pipelines are opening new avenues for biopharmaceutical contract manufacturers in Asia-Pacific. China’s pipelines have shown rapid growth in recent years. According to the International Society for Pharmaceutical Engineering, in 2016, the China Food and Drug Administration (CFDA) registered ~200 new biological pharmaceuticals entering clinical trials. Moreover, many CMOs are expanding their manufacturing capabilities to meet the growing demand, boosting the biopharmaceutical contract manufacturing market growth. For instance, in January 2020, STA Pharmaceutical Co. Ltd. (a subsidiary of WuXi AppTec) opened a new large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in China. Additionally, Bushu Pharmaceuticals expanded its contract-manufacturing pact with Amgen across Asia, which includes countries such as China, Taiwan, and South Korea. The CMO is expected to double its volume of Amgen products and will be responsible for assembly, labeling, packaging, and inspection of drugs, such as Repatha, Evenity, Prolia, and Xgeva. Similarly, in 2021, AstraZeneca contracted with JCR Pharmaceuticals in Japan to produce its COVID-19 vaccine solution. Further, JCR announced the decision to construct a new plant. These developments signify a significant emerging opportunity for pharmaceutical & biopharmaceutical companies in Asia-Pacific.
Strategic insights for the Asia Pacific Biopharmaceutical Contract Manufacturing provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 2,973.92 Million |
| Market Size by 2028 | US$ 5,462.23 Million |
| Global CAGR (2021 - 2028) | 9.1% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | Asia-Pacific
|
| Market leaders and key company profiles |
The geographic scope of the Asia Pacific Biopharmaceutical Contract Manufacturing refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The Asia Pacific Biopharmaceutical Contract Manufacturing Market is valued at US$ 2,973.92 Million in 2021, it is projected to reach US$ 5,462.23 Million by 2028.
As per our report Asia Pacific Biopharmaceutical Contract Manufacturing Market, the market size is valued at US$ 2,973.92 Million in 2021, projecting it to reach US$ 5,462.23 Million by 2028. This translates to a CAGR of approximately 9.1% during the forecast period.
The Asia Pacific Biopharmaceutical Contract Manufacturing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Biopharmaceutical Contract Manufacturing Market report:
The Asia Pacific Biopharmaceutical Contract Manufacturing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Biopharmaceutical Contract Manufacturing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Biopharmaceutical Contract Manufacturing Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Biopharmaceutical Contract Manufacturing Market
